Immunogenicity and Reactogenicity of a Novel Vaccine for Human Papillomavirus 16: A 2-Year Randomized Controlled Clinical Trial

Poland, Gregory A.; Jacobson, Robert M.; Koutsky, Laura A.; Tamms, Gretchen M.; Railkar, Radha; Smith, Judith F.; Bryan, Janine T.; Cavanaugh, Paul F.; Jansen, Kathrin U.; Barr, Eliav
May 2005
Mayo Clinic Proceedings;May2005, Vol. 80 Issue 5, p601
Academic Journal
OBJECTIVE: To evaluate the immunogenicity, reactogenicity, and tolerability of a prototype human papillomavirus (HPV) 16 virusilke particle (VLP) vaccine directed against the L1 capsid protein. SUBJECTS AND METHODS: We enrolled healthy nonpregnant women aged 18 to 26 years into a 2-year, double-blind, dose-ranging multicenter trial (October 12, 1998, to September 30, 2001). Subjects were assigned to study groups to receive a 3-dose regimen (day 0, month 2, and month 6) of 1 of 4 vaccine doses: 10 μg, 20 μg, 40 μg, or 80 μg or placebo. Serum anti-HPV 16 L1 antibody (sL1Ab) geometric mean titers (GMTs) were measured at day 0, at month 3, at month 7, and every 6 months for a total of 2 yeas using a radioimmunoassay. The primary immunogenicity analyses evaluated GMTs at month 7 in L1Ab-seronegative subjects at baseline. Vaccine tolerability was also assessed. RESULTS: A total of 480 subjects were randomized to receive placebo (n=52) or 10 μg (n=112), 20 μg (n=103), 40 μg (n=104), or 80 μg (n=107) of HPV 16 L1 VLP vaccine. At baseline, 75% of subjects were L1Ab seronegative. All vaccine doses produced a statistically significant sL1Ab response vs placebo (P<.001). At the completion of the vaccination regimen, sL1Ab GMTs in baseline-seronegative subjects were 36- to 78-told higher than the sL1Ab GMT at day 0 observed in subjects who had mounted an immune response to HPV 16 infection before enrollment. Serum L1Ab GMTs remained high throughout the 1.5-year postvaccinadon period. Poetvaccination sL1Ab GMTs were 1.1- to 2.4-fold higher in women who had detectable sL1Ab levels at enrollment compared with those in baseline-seronegative subjects, particularty in the persistence phase. The vaccine was generally well tolerated with no statistically significant differences in injection site or systemic adverse experiences among treatment groups. CONCLUSION: Immunization with this novel HPV 16 L1 VLP vaccine was well tolerated and produced an immunogenic response that persisted for at least 1.5 years after the final dose.


Related Articles

  • Vaccines in the public eye. Ritvo, Paul; Wilson, Kumanan; Willms, Dennis; Upshur, Ross; Goldman, Adam; Kelvin, David; Rosenthal, Kenneth L.; Rinfret, Aline; Kaul, Rupert; Krahn, Murray // Nature Medicine;Apr2005 Supplement, Vol. 11, p20 

    Preventive vaccines are widely acknowledged as the best hope for protection against infectious pathogens such as avian flu, HIV and SARS. As a result, they have received much recent attention in the media that has exposed some of the challenges involved in optimally using vaccine technology.

  • Combined Tetanus, Diphtheria, and 5-Component Pertussis Vaccine for Use in Adolescents and Adults. Pichichero, Michael E.; Rennels, Margaret B.; Edwards, Kathryn M.; Blatter, Mark M.; Marshall, Gary S.; Bologa, Monica; Wang, Elaine; Mills, Elaine // JAMA: Journal of the American Medical Association;6/22/2005, Vol. 293 Issue 24, p3003 

    Context Increasing reports of pertussis among US adolescents, adults, and their infant contacts have stimulated vaccine development for older age groups. Objective To assess the immunogenicity and reactogenicity of a tetanus-diphtheria 5-component (pertussis toxoid, filamentous hemagglutinin,...

  • Mucosal immunity and vaccines. Holmgren, Jan; Czerkinsky, Cecil // Nature Medicine;Apr2005 Supplement, Vol. 11, p45 

    There is currently great interest in developing mucosal vaccines against a variety of microbial pathogens. Mucosally induced tolerance also seems to be a promising form of immunomodulation for treating certain autoimmune diseases and allergies. Here we review the properties of the mucosal immune...

  • Can successful vaccines teach us how to induce efficient protective immune responses? Lambert, Paul-Henri; Liu, Margaret; Siegrist, Claire-Anne // Nature Medicine;Apr2005 Supplement, Vol. 11, p54 

    Some recently introduced vaccines that have excellent efficacy records have been developed without a clear understanding of their mechanism of protection. In fact, successful vaccines have often emerged out of empirical observations and have only rarely been the result of a rational use of the...

  • Ensuring safety of DNA vaccines. Glenting, Jacob; Wessels, Stephen // Microbial Cell Factories;2005, Vol. 4, p26 

    In 1990 a new approach for vaccination was invented involving injection of plasmid DNA in vivo, which elicits an immune response to the encoded protein. DNA vaccination can overcome most disadvantages of conventional vaccine strategies and has potential for vaccines of the future. However, today...

  • T cell vaccines for microbial infections. Robinson, Harriet L; Amara, Rama Rao // Nature Medicine;Apr2005 Supplement, Vol. 11, p25 

    Vaccination, or the deliberate induction of protective immunity by administering nonpathogenic forms of a microbe or its antigens to induce a memory immune response, is the world's most cost-effective medical procedure for preventing morbidity and mortality caused by infectious disease....

  • Targeting the innate immune response with improved vaccine adjuvants. Pashine, Achal; Valiante, Nicholas M; Ulmer, Jeffrey B // Nature Medicine;Apr2005 Supplement, Vol. 11, p63 

    Despite two centuries of vaccine use, only a few adjuvants and delivery systems are licensed for human use. This is partly because traditional vaccines based on attenuated live organisms already have them-their invasiveness provides efficient delivery to antigen-presenting cells and various...

  • Vaccines: past, present and future. Plotkin, Stanley A // Nature Medicine;Apr2005 Supplement, Vol. 11, p5 

    The vaccines developed over the first two hundred years since Jenner's lifetime have accomplished striking reductions of infection and disease wherever applied. Pasteur's early approaches to vaccine development, attenuation and inactivation, are even now the two poles of vaccine technology....

  • A new DTPw-HB/Hib combination vaccine for primary and booster vaccination of infants in Latin America. Tregnaghi, Miguel; López, Pio; Rocha, Crisanta; Rivera, Luis; David, Marie-Pierre; Rüttimann, Ricardo; Schuerman, Lode // Revista Panamericana de Salud Publica;Mar2006, Vol. 19 Issue 3, p179 

    Objectives. In 1998 the World Health Organization (WHO) recommended the inclusion of Haemophilus influenza type B (Hib) conjugate vaccines in infant immunization programs, whenever in accordance with national priorities. GlaxoSmithKline Biologicals has developed a new pentavalent combined...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics